JP2003531601A - コルチコトロピン放出因子受容体ＣＲＦ２αのプロモーター配列の活性を変化させる因子の同定法 - Google Patents
コルチコトロピン放出因子受容体ＣＲＦ２αのプロモーター配列の活性を変化させる因子の同定法Info
- Publication number
- JP2003531601A JP2003531601A JP2001580188A JP2001580188A JP2003531601A JP 2003531601 A JP2003531601 A JP 2003531601A JP 2001580188 A JP2001580188 A JP 2001580188A JP 2001580188 A JP2001580188 A JP 2001580188A JP 2003531601 A JP2003531601 A JP 2003531601A
- Authority
- JP
- Japan
- Prior art keywords
- crf
- receptor
- promoter
- cell line
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 27
- 108010056643 Corticotropin-Releasing Hormone Receptors Proteins 0.000 title description 3
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims abstract description 43
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims abstract description 29
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 230000009261 transgenic effect Effects 0.000 claims abstract description 18
- 108700008625 Reporter Genes Proteins 0.000 claims abstract description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 12
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 11
- 238000012360 testing method Methods 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 101710113174 Corticoliberin Proteins 0.000 claims description 79
- GBONBLHJMVUBSJ-FAUHKOHMSA-N corticorelin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 GBONBLHJMVUBSJ-FAUHKOHMSA-N 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 21
- 238000011144 upstream manufacturing Methods 0.000 claims description 20
- 101000895481 Homo sapiens Corticoliberin Proteins 0.000 claims description 17
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 12
- 101000895495 Rattus norvegicus Corticoliberin Proteins 0.000 claims description 11
- 101000898072 Homo sapiens Calretinin Proteins 0.000 claims 4
- 101000806138 Homo sapiens Dehydrogenase/reductase SDR family member 4 Proteins 0.000 claims 4
- 101000898066 Rattus norvegicus Calretinin Proteins 0.000 claims 1
- 101000806172 Rattus norvegicus Dehydrogenase/reductase SDR family member 4 Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 81
- 102100021752 Corticoliberin Human genes 0.000 description 62
- 108020003175 receptors Proteins 0.000 description 53
- 102000005962 receptors Human genes 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 24
- 241000700159 Rattus Species 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000035882 stress Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 12
- 208000019901 Anxiety disease Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 230000036506 anxiety Effects 0.000 description 9
- 108700019146 Transgenes Proteins 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108090000331 Firefly luciferases Proteins 0.000 description 5
- 108010005774 beta-Galactosidase Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 229940035613 prozac Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100032165 Corticotropin-releasing factor-binding protein Human genes 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101100321669 Fagopyrum esculentum FA02 gene Proteins 0.000 description 1
- 102100036738 Guanine nucleotide-binding protein subunit alpha-11 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100283445 Homo sapiens GNA11 gene Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000895490 Mus musculus Corticoliberin Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101001094026 Synechocystis sp. (strain PCC 6803 / Kazusa) Phasin PhaP Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100029793 Urocortin Human genes 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 108010083720 corticotropin releasing factor-binding protein Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000001094 effect on targets Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20112900P | 2000-05-02 | 2000-05-02 | |
| US60/201,129 | 2000-05-02 | ||
| PCT/US2001/013920 WO2001083563A2 (en) | 2000-05-02 | 2001-04-30 | Method of identifying agents that alter the activity of the promoter sequence for crf receptor 2-alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2003531601A true JP2003531601A (ja) | 2003-10-28 |
Family
ID=22744599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001580188A Pending JP2003531601A (ja) | 2000-05-02 | 2001-04-30 | コルチコトロピン放出因子受容体ＣＲＦ２αのプロモーター配列の活性を変化させる因子の同定法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20020032912A1 (de) |
| EP (1) | EP1279038B1 (de) |
| JP (1) | JP2003531601A (de) |
| AT (1) | ATE283480T1 (de) |
| AU (1) | AU2001295192A1 (de) |
| CA (1) | CA2407834A1 (de) |
| DE (1) | DE60107413D1 (de) |
| WO (1) | WO2001083563A2 (de) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965790A (en) * | 1997-03-06 | 1999-10-12 | Millennium Pharmaceuticals, Inc. | SR-BI regulatory sequences and therapeutic methods of use |
-
2001
- 2001-04-30 JP JP2001580188A patent/JP2003531601A/ja active Pending
- 2001-04-30 AT AT01973779T patent/ATE283480T1/de not_active IP Right Cessation
- 2001-04-30 EP EP01973779A patent/EP1279038B1/de not_active Expired - Lifetime
- 2001-04-30 DE DE60107413T patent/DE60107413D1/de not_active Expired - Lifetime
- 2001-04-30 CA CA002407834A patent/CA2407834A1/en not_active Abandoned
- 2001-04-30 AU AU2001295192A patent/AU2001295192A1/en not_active Abandoned
- 2001-04-30 US US09/847,852 patent/US20020032912A1/en not_active Abandoned
- 2001-04-30 WO PCT/US2001/013920 patent/WO2001083563A2/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001295192A1 (en) | 2001-11-12 |
| EP1279038B1 (de) | 2004-11-24 |
| DE60107413D1 (de) | 2004-12-30 |
| US20020032912A1 (en) | 2002-03-14 |
| EP1279038A2 (de) | 2003-01-29 |
| WO2001083563A3 (en) | 2002-07-04 |
| CA2407834A1 (en) | 2001-11-08 |
| ATE283480T1 (de) | 2004-12-15 |
| WO2001083563A2 (en) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Serafini et al. | Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system | |
| Yoshihara et al. | OCAM: a new member of the neural cell adhesion molecule family related to zone-to-zone projection of olfactory and vomeronasal axons | |
| Welle et al. | Muscle growth after postdevelopmental myostatin gene knockout | |
| DE60314236T2 (de) | Verfahren zur diagnose und therapie von schizophrenie | |
| Zerucha et al. | A highly conserved enhancer in the Dlx5/Dlx6Intergenic region is the site of cross-regulatory interactions betweenDlx genes in the embryonic forebrain | |
| Morkin | Regulation of myosin heavy chain genes in the heart. | |
| Kobayashi et al. | HRG4 (UNC119) mutation found in cone–rod dystrophy causes retinal degeneration in a transgenic model | |
| Rawson et al. | Expression of mRNAs encoding for two different olfactory receptors in a subset of olfactory receptor neurons | |
| Lazartigues et al. | Brain-selective overexpression of angiotensin (AT1) receptors causes enhanced cardiovascular sensitivity in transgenic mice | |
| AU691469B2 (en) | DNA encoding taurine and gaba transporters and uses thereof | |
| JPH09509314A (ja) | 神経ペプチドｙ／ペプチドｙｙ（ｙ２）受容体をコードした核酸、及び該核酸の使用 | |
| CA2428754A1 (en) | Corticotropin releasing factor receptor 2 deficient mice and uses thereof | |
| AU780829B2 (en) | Corticotropin releasing factor receptor 2 deficient mice and uses thereof | |
| DE69722035T2 (de) | Neue testmethode, um den differenzierungszustand von bauchspeicheldrüsenzellen eines säugetieres festzustellen. | |
| Szczygieł et al. | Gene therapy vector encoding neuropeptide Y and its receptor Y2 for future treatment of epilepsy: preclinical data in rats | |
| Bullock et al. | Lysosomal storage disease associated with a CNP sequence variant in Dalmatian dogs | |
| JP2002503460A (ja) | 創傷治癒のための組成物および方法 | |
| JP2003513645A (ja) | メラノコルチン−３レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法 | |
| AU729532B2 (en) | Melatonin 1a receptor gene regulatory regions and uses thereof | |
| JP2003531601A (ja) | コルチコトロピン放出因子受容体ＣＲＦ２αのプロモーター配列の活性を変化させる因子の同定法 | |
| US5559021A (en) | DNA encoding a novel mammalian transporter homologous to neurotransmitter transporters and uses thereof | |
| Kim et al. | The promoter of brain-specific angiogenesis inhibitor 1-associated protein 4 drives developmentally targeted transgene expression mainly in adult cerebral cortex and hippocampus | |
| AU730141B2 (en) | Transgenic animals with disrupted npy y1 receptor genes | |
| Roosa et al. | Structure, biological activity of the upstream regulatory sequence, and conserved domains of a middle molecular mass neurofilament gene of Xenopus laevis | |
| US7531356B2 (en) | Promoter sequences for corticotropin releasing-factor receptor CRF2α and method of identifying agents that alter the activity of the promoter sequences |